# A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery

> **NCT00554359** · PHASE1 · COMPLETED · sponsor: **Quark Pharmaceuticals** · enrollment: 16 (actual)

## Conditions studied

- Injury of Kidney
- Acute Renal Failure

## Interventions

- **DRUG:** I5NP (a small interfering RNA)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00554359
- **Lead sponsor:** Quark Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2010-10
- **Final completion:** 2010-11
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2011-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00554359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00554359, "A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00554359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*